Resumen de las cotizaciones máximas, mínimas y variaciones del Moderna
Precios históricos de las acciones
Precio actual de la acción	US$79.76
Máximo en las últimas 52 semanas	US$81.40
Mínimo de 52 semanas	US$22.28
Beta	0.94
Cambio en 1 mes	62.58%
Variación en 3 meses	62.11%
Cambio de 1 año	161.59%
Variación en 3 años	-32.90%
Variación en 5 años	-65.74%
Variación desde la OPV	328.82%

Noticias y actualizaciones recientes

Actualización de narrativa • Jun 29

MRNA: Flu Approval Progress Will Still Limit Long Term Upside

Moderna's updated analyst price target framework reflects a modest fair value adjustment to about $44.25 per share, along with higher modeled revenue growth and profit margins and a lower future P/E multiple, as analysts factor in supportive regulatory commentary on the mRNA flu program and incremental optimism around the broader vaccine pipeline. Analyst Commentary Recent Street research around Moderna highlights a mix of optimism tied to the mRNA flu and broader vaccine pipeline, and caution around timing, clinical data gaps, and execution risk.

Seeking Alpha • Jun 23

Moderna: The Comeback Is Now In Full Swing

Summary Moderna, Inc. is transitioning from Covid-era reliance to a diversified mRNA pipeline, with a cautious buy rating and a suggested entry below $50. MRNA's mFlusiva flu vaccine highlights benefits of mRNA vaccines (speed, flexibility, manufacturing efficiency), showing superior efficacy to incumbents, with FDA approval expected soon and blockbuster potential driving 2027+ revenue ramp. Pipeline catalysts include mCombriax (Covid/Flu combo vaccine), oncology (Intismeran Autogene), and rare disease programs, supported by a solid $5.2B cash position. Key MRNA risks include vaccine sentiment shifts, ongoing litigation, and near-term revenue softness, but long-term growth is underpinned by late-stage assets. Read the full article on Seeking Alpha

Artículo de análisis • Jun 21

Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing

Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older. See our latest analysis for Moderna. Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests...

Recent updates

Actualización de narrativa • Jun 29

MRNA: Flu Approval Progress Will Still Limit Long Term Upside

Seeking Alpha • Jun 23

Moderna: The Comeback Is Now In Full Swing

Artículo de análisis • Jun 21

Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing

Actualización de narrativa • Jun 15

MRNA: Flu Review And Pipeline Execution Risk Are Expected To Restrain Upside

Moderna's updated analyst price target edges higher, with the model fair value moving from $21.00 to about $21.09 as analysts factor in slightly stronger revenue growth expectations and potential upside from norovirus vaccine penetration. Analyst Commentary Recent Street research on Moderna clusters around cautious optimism, with several firms adjusting price targets while still highlighting meaningful risks tied to execution and future growth drivers, especially in vaccines beyond Covid.

Actualización de narrativa • Jun 01

MRNA: Flu Review And Litigation Overhang Will Continue To Restrain Upside

Analysts raised Moderna’s fair value estimate from $12.00 to $21.00, citing a series of higher Street price targets and updated assumptions for margins, litigation risk, and future P/E multiples. Analyst Commentary Recent Street research around Moderna has centered on two themes: valuation reset after the litigation settlement and differing views on how much residual legal and execution risk still matters for the stock.

Actualización de narrativa • May 13

MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome

Narrative Update on Moderna Analysts have collectively raised their Moderna price targets by low to mid single digit dollar amounts, citing updated models that reflect recent litigation settlements, FDA progress on the flu vaccine, and oncology pipeline developments. Together, these factors support a lower fair value estimate of $66.29, a slightly higher discount rate of 7.21%, adjusted revenue growth expectations of 52.59%, a profit margin of 4.12%, and a future P/E assumption of 107.40x.

Actualización de narrativa • Apr 27

MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside

Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.

Actualización de narrativa • Apr 13

MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside

Analysts have nudged Moderna's average price target higher by $5, reflecting a mix of renewed confidence in the company's vaccine pipeline after the FDA's reconsideration of its flu shot application and reduced litigation overhang following recent settlement developments. Analyst Commentary Recent research on Moderna clusters around two main themes for you to watch closely: valuation reset around the vaccine pipeline and lingering legal and execution risks tied to the COVID and flu franchises.

Actualización de narrativa • Mar 30

MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside

Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.

Actualización de narrativa • Mar 16

MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside

Analysts have trimmed Moderna's implied fair value from $15.00 to $12.00 as they factor in a higher discount rate, more moderate profit margins and updated views on revenue growth following recent litigation settlements and regulatory updates. Analyst Commentary Street research around Moderna centers on two themes that matter for you as an investor: the clean-up of legal overhangs and how much confidence to place in the broader vaccine and oncology pipeline.

Actualización de narrativa • Mar 02

MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision

Our fair value estimate for Moderna has inched up by about $1.65 per share to $91.97 as analysts update their models around higher projected product sales, a more constructive FDA review path for the mRNA-1010 flu vaccine with an August 5 PDUFA date, and refreshed views on the broader late stage pipeline including oncology. Analyst Commentary Street research on Moderna has leaned more constructive around the updated regulatory path for flu vaccine mRNA-1010, the broader late stage pipeline, and recent quarterly disclosures.

Artículo de análisis • Feb 17

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest annual results with some very strong...

Actualización de narrativa • Feb 16

MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes

Analysts have nudged their average price target for Moderna higher by about $3, reflecting updated views on long term revenue potential, profit margins and a higher future P/E multiple following recent research on COVID demand, the broader vaccine pipeline and legal outcomes. Analyst Commentary Recent Street research on Moderna highlights a mix of caution and growing optimism, with several bullish analysts adjusting their models after company updates, legal developments and new financing disclosures.

Artículo de análisis • Feb 02

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Despite an already strong run, Moderna, Inc. ( NASDAQ:MRNA ) shares have been powering on, with a gain of 43% in the...

Actualización de narrativa • Feb 01

MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside

The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple. Analyst Commentary Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern.

Actualización de narrativa • Jan 18

MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential

Narrative update We trim our analyst price target for Moderna from about US$121 to roughly US$87 as analysts factor in lower profit margin expectations, a higher discount rate, cautious views on COVID-related revenue visibility, and a more binary risk profile around key late stage vaccine data, even as some models reflect higher revenue growth assumptions and updated financing terms. Analyst Commentary Recent Street research on Moderna points to a mixed backdrop, with several firms reaffirming cautious stances while still recognizing specific areas where execution and funding choices could support long term value creation.

Actualización de narrativa • Jan 04

MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation

Analysts have modestly lifted their price targets on Moderna, with recent revisions such as $15 to $18, $16 to $17, and $32 to $30. These changes collectively reflect slightly improved conviction in the company’s long term revenue growth, gross margin expansion, and strengthened liquidity following new Ares financing, despite ongoing profitability and litigation risks.

Actualización de narrativa • Dec 21

MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks

Analysts have modestly raised their price target on Moderna to align with a slightly higher fair value estimate of about $36.75, citing incremental improvements in long term revenue growth and profitability assumptions supported by recent Investor and Analyst Day updates, revised 2026 to 2028 guidance, and Ares financing. Analyst Commentary Recent Street research reflects a cautious but incrementally more constructive stance toward Moderna, with several firms refining their models following Investor and Analyst Day presentations and the announcement of new financing.

Artículo de análisis • Dec 19

There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 28% share price jump in the last...

Actualización de narrativa • Dec 07

MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk

Analysts have modestly lowered their price target on Moderna to about $35.78 from $37.32 per share, reflecting slightly softer long term growth and valuation assumptions. This comes even as recent Investor and Analyst Day updates, new debt financing and evolving oncology data support a more stable cash outlook and gradual margin improvement.

Actualización de narrativa • Nov 23

MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts

Analysts have revised their fair value estimate for Moderna down from approximately $40.30 to $37.32. They cited the company’s updated revenue growth projections and cost outlook, despite improvements in profit margins and continued progress across its commercial and research pipelines.

Actualización de narrativa • Nov 07

MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties

Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.

Actualización de narrativa • Oct 23

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Moderna’s analyst price target has been revised downward from $44.25 to $40.30. Analysts cite lower projected revenue growth along with persistent regulatory and profitability challenges, which have been reflected in recent industry commentary.

Actualización de narrativa • Sep 04

Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential

Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.

Artículo de análisis • Jul 18

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 26% share price jump in the last...

Nueva narrativa • May 02

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and

Seeking Alpha • Apr 22

More Downside For Moderna Before The Breakthrough

Summary Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires investor patience, with key vaccines in Phase 3 trials but regulatory approvals potentially years away. Financials are sound enough to support long term research, with a significant cash buffer, but oncology research faces regulatory and technical challenges. Shares are likely to go down before any uptrend (2-3 years horizon). Read the full article on Seeking Alpha

Seeking Alpha • Mar 31

FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)

Summary Moderna's stock dropped over 10% after the FDA's Dr. Peter Marks resigned, signaling potential increased regulatory scrutiny on vaccines. Moderna's financial health remains strong, with ~$9 billion in cash and investments, but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's revenue outlook. Given the negative public perception of mRNA technology and regulatory risks, I downgrade MRNA to "Hold" until more clarity emerges. Read the full article on Seeking Alpha

Seeking Alpha • Mar 06

Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out

Summary Moderna, Inc.'s stock surged 16% yesterday after a German court ruled Pfizer and BioNTech may have violated Moderna's COVID-19 vaccine patent, potentially leading to compensation. Despite the ruling, Pfizer and BioNTech will appeal, while previous court decisions have invalidated related patents, complicating Moderna's legal victory. MRNA's business struggles post-pandemic, with declining revenues and few new products, have made litigation a potentially critical revenue source, which I'd call a red flag. The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products since 2022, instead of one, it's unlikely yesterday's news would have moved its share price, but this reflects the new reality of messenger-RNA, a technology that hasn't lived up to the hype — yet. Read the full article on Seeking Alpha

Seeking Alpha • Feb 14

Moderna, Inc.: Working Hard But Competition Is Working Harder

Summary MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition. Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Read the full article on Seeking Alpha

Nueva narrativa • Feb 09

Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks

Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.

Seeking Alpha • Feb 03

Moderna: The Good News Isn't Enough

Summary I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock. I argue why I don't think anything has changed materially, reinforcing my SELL rating. Despite cost-cutting measures, I am concerned that reducing R&D will hurt Moderna's research capabilities, preferring cuts in SG&A instead. Read the full article on Seeking Alpha

Seeking Alpha • Jan 10

Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)

Summary Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential. The company's cost-cutting measures may hinder innovation, but rising COVID cases and bird flu risks could uniquely benefit Moderna if a pandemic occurs. Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads significantly. With only a 5% chance of a bird flu pandemic, I believe Moderna is a hold, awaiting further developments on the bird flu's virality. Read the full article on Seeking Alpha

Seeking Alpha • Dec 31

Moderna: 2025 Contrarian Play

Summary Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses. Investors should consider buying the beaten-down stock around $40, anticipating higher sales and multiple big approvals in the coming years. Read the full article on Seeking Alpha

Seeking Alpha • Dec 18

Moderna: Cutting Costs Might Not Be Enough

Summary Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. MRNA has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. Read the full article on Seeking Alpha

Seeking Alpha • Nov 22

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Summary Moderna, Inc.'s stock has plummeted over 75% in 2024, driven by disappointing earnings, reduced revenue forecasts, and now the threat of a vaccine skeptic, RFK Jr.'s potential confirmation to lead HHS. Despite two commercialized vaccines and positive Phase 3 results for others, Moderna faces uncertainty in achieving profitability before 2028, with significant R&D expenses and competitive pressures. The private COVID-19 vaccine market is considered stable but limited, and the RSV vaccine faces competition from GSK and Pfizer, and likely restriction to a once-every 3-year dose. A potential acquisition by a Big Pharma like Merck could bring fresh R&D perspectives, but Moderna may need to consider further program cuts to achieve profitability in a shorter time-frame. Read the full article on Seeking Alpha

Seeking Alpha • Oct 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Summary GSK's lawsuit against Moderna over lipid nanoparticle technology could severely impact Moderna's revenue from Spikevax and mResvia, and delay their breakeven point. The lawsuit adds uncertainty to MRNA's already declining stock, increasing short-selling activity and potentially leading to prolonged negative headlines. Despite the legal risks, I plan to trade MRNA, looking for a reversion play if the ticker breaks its downtrend with elevated volume. I am lowering my MRNA conviction level from 3 to 2 out of 5 and moving it to the speculative “Bio Boom” portfolio. Read the full article on Seeking Alpha

Rentabilidad de los accionistas

	MRNA	US Biotechs	Mercado US
7D	18.6%	5.4%	1.4%
1Y	161.6%	41.5%	19.1%

Rentabilidad vs. Industria: MRNA superó a la industria US Biotechs, que obtuvo un rendimiento del 41.5% el año pasado.

Rentabilidad vs. Mercado: MRNA superó al mercado US, que obtuvo un rendimiento del 19.1% el año pasado.

Volatilidad de los precios

Is MRNA's price volatile compared to industry and market?
MRNA volatility
MRNA Average Weekly Movement	9.8%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Precio estable de las acciones: MRNA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MRNA (10%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2010	4,700	Stéphane Bancel	www.modernatx.com

Moderna, Inc, empresa de biotecnología, suministra medicamentos de ARN mensajero en Estados Unidos, Europa y a escala internacional. Las vacunas respiratorias de la empresa incluyen spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, la vacuna contra la gripe estacional, la vacuna combinada y la vacuna contra la gripe pandémica; las vacunas latentes comprenden las vacunas contra el citomegalovirus, el virus de Epstein-Barr y el virus de la inmunodeficiencia humana; los virus entéricos incluyen el norovirus; las vacunas de salud pública consisten en las vacunas contra el Zika, Nipah y Mpox; y las vacunas contra enfermedades bacterianas, como las vacunas contra el lyme. También ofrece productos terapéuticos oncológicos, como el autogen intismeran, la terapia antigénica del cáncer, el activador de células t y el potenciador de terapia celular; y productos para enfermedades raras, como la acidemia propiónica y metilmalónica, y la fibrosis quística.

Resumen de fundamentos de Moderna, Inc.

¿Cómo se comparan los beneficios e ingresos de Moderna con su capitalización de mercado?
Estadísticas fundamentales de MRNA
Capitalización bursátil	US$31.69b
Beneficios(TTM)	-US$3.19b
Ingresos (TTM)	US$2.23b

14.2x

Ratio precio-ventas (PS)

-9.9x

Ratio precio-beneficio (PE)

¿Está MRNA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MRNA
Ingresos	US$2.23b
Coste de los ingresos	US$3.78b
Beneficio bruto	-US$1.55b
Otros gastos	US$1.64b
Beneficios	-US$3.19b

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-8.05
Margen bruto	-69.89%
Margen de beneficio neto	-143.55%
Ratio deuda/patrimonio	8.0%

¿Cómo se ha desempeñado MRNA a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/07/03 05:29
Precio de las acciones al final del día	2026/07/02 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Moderna, Inc. está cubierta por 42 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
null null	Argus Research Company
Eliana Merle	Barclays
Huidong Wang	Barclays

Moderna (MRNA) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Inflated Valuation Will Choke Revenue Amid Tighter Global Scrutiny

Global Preventative Medicine Demand And mRNA Pipelines Will Transform Healthcare

Top Community Narratives

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Top Community Narratives

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Top Analyst Narratives

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts

Inflated Valuation Will Choke Revenue Amid Tighter Global Scrutiny

Global Preventative Medicine Demand And mRNA Pipelines Will Transform Healthcare

Competidores de Moderna, Inc.

BioNTech

Biogen

United Therapeutics

Incyte

Historial de precios y rendimiento

Noticias y actualizaciones recientes

FDA Panel Backs Moderna mRNA Flu Vaccine as Company Expands Cancer and Autoimmune Pipeline

MRNA: Flu Approval Progress Will Still Limit Long Term Upside

FDA Panel Backs Moderna mRNA Flu Vaccine for Adults 50 and Older

Moderna: The Comeback Is Now In Full Swing

Moderna Receives Unanimous FDA Panel Recommendation for mRNA-Based Influenza Vaccine for Adults 50 and Older

Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing

Recent updates

FDA Panel Backs Moderna mRNA Flu Vaccine as Company Expands Cancer and Autoimmune Pipeline

MRNA: Flu Approval Progress Will Still Limit Long Term Upside

FDA Panel Backs Moderna mRNA Flu Vaccine for Adults 50 and Older

Moderna: The Comeback Is Now In Full Swing

Moderna Receives Unanimous FDA Panel Recommendation for mRNA-Based Influenza Vaccine for Adults 50 and Older

Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing

Moderna Shares Climb as FDA mFlusiva Review Nears and Multiple Vaccine Launches Planned

Moderna Plans Multiple Product Launches in 2027 and 2028

President notifies of intention to sell stock

MRNA: Flu Review And Pipeline Execution Risk Are Expected To Restrain Upside

Moderna Reports Strong Five-Year Melanoma Vaccine Data and Expands Ebola Program with CEPI Funding

MRNA: Flu Review And Litigation Overhang Will Continue To Restrain Upside

President notifies of intention to sell stock

MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.3% to US$41.42

Consensus EPS estimates fall by 10%

MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside

Moderna, Inc. to Report Q1, 2026 Results on May 01, 2026

MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside

MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside

Moderna, Inc., Annual General Meeting, May 06, 2026

MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement with Moderna

MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision

President notifies of intention to sell stock

Price target increased by 7.2% to US$41.60

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010

Arbutus Biopharma Corporation Announces Court Ruling on Patent Infringement Dispute over Lipid Nanoparticle Vaccine Technology

Now 20% overvalued after recent price rise

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside

Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026

Moderna, Inc. to Report Q4, 2025 Results on Feb 13, 2026

MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential

New minor risk - Share price stability

MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation

MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks

There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

CEO & Director exercised options to buy US$21m worth of stock.

Insider exercised options and sold US$582k worth of stock

Insider exercised options and sold US$582k worth of stock

MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk

Price target decreased by 10% to US$35.78

MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts

Consensus estimates of losses per share improve by 18%

Moderna, Inc. Lowers Earnings Guidance for Full Year 2025

MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties